,24 Also, another phase 3 prospective study comparing different chemotherapy regimens as an adjuvant setting for early-stage NSCLC exhibited significantly improved survival with vinorelbine, a similar anti-microtubule agent as (nab)paclitaxel, compared to traditional pemetrexed in EGFR-mutant LUAD,39 implying that a (nab)paclitaxel-based regimen might be an ideal option for EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.